

# UCSF

## UC San Francisco Previously Published Works

### Title

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.

### Permalink

<https://escholarship.org/uc/item/50h4z987>

### Authors

Al Sukhun, Sana

Temin, Sarah

Barrios, Carlos

et al.

### Publication Date

2024

### DOI


















10.1200/GO.23.00285

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline

Sana Al Sukhun, MD, MSc, FASCO<sup>1</sup> ; Sarah Temin, MSPH<sup>2</sup> ; Carlos H. Barrios, MD<sup>3</sup> ; Nicoleta Zenovia Antone, MD<sup>4</sup> ; Yanin Chavarri Guerra, MD, MSc<sup>5</sup> ; Mariana Chavez-MacGregor, MD, MSc, FASCO<sup>6</sup> ; Rakesh Chopra, MD<sup>7</sup>; Michael A. Danso, MD, FASCO<sup>8</sup>; Henry Leonidas Gomez, MD, PhD<sup>9</sup> ; N'Da Marcelin Homian, MD<sup>10</sup> ; Alaa Kandil, MD<sup>11</sup> ; Benda Kithaka<sup>12</sup> ; Bogda Koczwara, MD<sup>13</sup> ; Beverly Moy, MD, FASCO, MPH<sup>14</sup> ; Gertrude Nakigudde<sup>15</sup> ; Fernando Enrique Petracci, MD<sup>16</sup> ; Hope S. Rugo, MD, FASCO<sup>17</sup> ; Nagi S. El Saghir, MD, FASCO<sup>18</sup> ; and Banu K. Arun, MD<sup>6</sup> 

DOI <https://doi.org/10.1200/GO.23.00285>

## ABSTRACT

**PURPOSE** To guide clinicians and policymakers in three global resource–constrained settings on treating patients with metastatic breast cancer (MBC) when Maximal setting–guideline recommended treatment is unavailable.



**METHODS** A multidisciplinary, multinational panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes.

**RESULTS** Four published resource–agnostic guidelines were adapted for resource–constrained settings; informing two rounds of formal consensus; recommendations received  $\geq 75\%$  agreement.

**RECOMMENDATIONS** Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first–line, for hormone receptor (HR)–positive MBC, when a non–steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone. For life–threatening disease, use single–agent chemotherapy or surgery for local control. For premenopausal patients, use ovarian suppression or ablation plus hormone therapy in Basic settings. For human epidermal growth factor receptor 2 (HER2)–positive MBC, if trastuzumab, pertuzumab, and chemotherapy are unavailable, use trastuzumab and chemotherapy; if unavailable, use chemotherapy. For HER2–positive, HR–positive MBC, use standard first–line therapy, or endocrine therapy if contraindications. For triple–negative MBC with unknown PD–L1 status, or if PD–L1–positive and immunotherapy unavailable, use single–agent chemotherapy. For germline *BRCA1/2* mutation–positive MBC, if poly(ADP–ribose) polymerase inhibitor is unavailable, use hormonal therapy (HR–positive MBC) and chemotherapy (HR–negative MBC). In second–line, for HR–positive MBC, Enhanced setting recommendations depend on prior treatment; for Limited, use tamoxifen or chemotherapy. For HER2–positive MBC, if trastuzumab deruxtecan is unavailable, use trastuzumab emtansine; if unavailable, capecitabine and lapatinib; if unavailable, trastuzumab and/or chemotherapy (hormonal therapy alone for HR–positive MBC).

Additional information is available at [www.asco.org/resource-stratified-guidelines](http://www.asco.org/resource-stratified-guidelines). It is ASCO's view that healthcare providers and system decision–makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.

## ACCOMPANYING CONTENT

 Appendix  
 Data Supplement

Accepted November 22, 2023  
Published January 10, 2024

Evidence Based Medicine  
Committee approval:  
July 31, 2023

JCO Global Oncol 10:e2300285  
© 2024 by American Society of  
Clinical Oncology

Licensed under the Creative  
Commons Attribution 4.0 License

## INTRODUCTION

The purpose of this guideline is to provide expert guidance on the systemic treatment of metastatic breast cancer (MBC)

to clinicians, public health leaders, patients, and policy–makers in resource–constrained settings. This guideline's target population is adult patients with MBC in resource–constrained settings, and it focuses on medical treatment.

## THE BOTTOM LINE

### Systemic Treatment of Patients with Metastatic Breast Cancer: ASCO Resource–Stratified Guideline

#### GUIDELINE QUESTION

What is the optimal treatment for patients diagnosed with metastatic breast cancer in resource-constrained settings?

#### TARGET POPULATION

Adult patients with metastatic breast cancer in resource-constrained settings.

#### TARGET AUDIENCE

Clinicians, public health leaders, patients, and policymakers in resource-constrained settings

#### METHODS

A multinational, multidisciplinary Expert Panel was convened to develop clinical practice guideline recommendations on the basis of an expert consensus process.

Author's note. It is the view of ASCO that health care providers and health care system decision-makers should be guided by the recommendations for the highest stratum of resources available. The guidelines are intended to complement but not replace local guidelines.

#### RECOMMENDATIONS

##### General Notes

1. Palliative care needs should be addressed for all patients at presentation of metastatic breast cancer (MBC), including situations in which no antineoplastic interventions are accessible.
2. Patients who are premenopausal can only receive aromatase inhibitors if accompanied by ovarian ablation or ovarian suppression.
3. Clinicians should recommend treatment according to pathological and biomarker features when quality (following established guidelines) testing results are available.
4. Cases should be discussed using a multidisciplinary approach with the core team including the surgeon, pathologist, oncologist, and radiation oncologist.

##### First-Line

###### *Hormone Receptor–Positive*

Assessment of menopausal status is critical; ovarian suppression or ablation should be provided to patients who are premenopausal. Patients whose tumors express any level of hormone receptors (HRs) should be offered hormone therapy. In Basic settings, if no immunohistochemistry testing is available, clinicians may presume HR positivity and offer tamoxifen in most cases.

For patients with HR-positive, human epidermal growth factor receptor 2 (HER2)–negative MBC, when non-steroidal aromatase inhibitors (AIs) and CDK 4/6 inhibitors are not available, use hormonal therapy alone. For life-threatening disease, clinicians may use single-agent chemotherapy; surgery may be used in cases in need of “salvage mastectomies” and for local control.

For patients with HR-positive, HER2-negative MBC who are premenopausal, ovarian suppression or ablation plus hormone therapy should be offered.

Patients with HR-positive, HER2-negative MBC for whom chemotherapy is offered, should be prescribed single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease.

Patients with HR-positive MBC with disease progression on an endocrine agent who are postmenopausal may be offered treatment with either:

- endocrine therapy with or without targeted therapy or
- single-agent chemotherapy.

Patients with HR-positive MBC who are premenopausal without prior hormone therapy may be offered treatment with:

- Tamoxifen, or ovarian ablation or ovarian suppression alone, or sequential hormonal therapy, or non-steroidal AIs with ovarian ablation or ovarian suppression and CDK4/6 inhibitors in Enhanced settings.
- Tamoxifen, or ovarian ablation or ovarian suppression with hormonal therapy in Limited settings.
- Tamoxifen in Basic settings.

Patients with HR-positive MBC with disease progression on an endocrine agent who are premenopausal may be offered treatment with:

- Ovarian ablation or ovarian suppression with hormonal therapy or sequential hormone therapy in Enhanced settings.
- Alternative hormone therapy or surgery in Limited settings.

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

- Tamoxifen and bilateral oophorectomy in Basic settings.

### *HER2-Positive*

HER2-targeted therapy is recommended for patients with HER2-positive advanced BC, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis.

Trastuzumab, pertuzumab, and taxanes for first-line treatment are recommended. If pertuzumab isn't available, then clinicians may offer chemotherapy and trastuzumab in Enhanced settings. Chemotherapy may be offered in Limited settings.

For patients with HER2-positive and HR-positive MBC, various HER2-targeted therapies and chemotherapy or endocrine therapy, or chemotherapy alone or endocrine therapy alone may be offered depending on availability of anti-HER2 therapies. See [Table 5](#) for special circumstances for this population.

### *Triple-Negative*

Patients with triple-negative MBC that is known PD-L1 –positive may be offered the addition of an immune checkpoint inhibitor to chemotherapy as first-line therapy in Enhanced settings; most patients with triple-negative MBC in Limited settings may be offered chemotherapy.

Patients with triple-negative, PD-L1 –negative MBC should be offered single-agent chemotherapy rather than combination chemotherapy as first-line treatment.

For *BRCA1* or *BRCA2* mutation carriers with metastatic HR-negative, HER2-negative BC, poly(ADP-ribose) polymerase inhibitor (PARPi) therapy may be offered in Enhanced settings.

Patients with HR-positive MBC and known *BRCA* mutations and if PARPi therapy is not available, treatment options include hormonal therapy with or without ovarian ablation.

## **Second-Line**

### *HR-Positive*

In Enhanced settings, recommendations depend on prior treatment, for example, with prior endocrine therapy, clinicians may offer second-line endocrine therapy with or without targeted therapy (eg, CDK4/6 inhibitor or everolimus). In Limited settings with prior endocrine therapy, clinicians may offer second-line endocrine therapy if available, otherwise, they may offer chemotherapy.

### *HER2-Positive*

HER2-targeted therapy should be given based on prior therapy and HR status. Trastuzumab deruxtecan or alternate HER2-targeted therapy regimens may be offered as second-line treatment depending on availability. In Limited settings, chemotherapy may be offered (with trastuzumab, if available). In Basic settings, if a patient has received prior treatment and medical treatment and pathology aren't available and has symptoms, clinicians may offer primary surgery for palliative reasons, including local control. If a patient finished trastuzumab-based adjuvant treatment less than 1 year before recurrence, offer second-line options. If more than 1 year before recurrence, offer first-line options.

### *HR-Positive, BRCA1/2 Mutations*

Patients with HR-positive MBC with germline *BRCA1/2* mutations no longer benefiting from endocrine therapy may be offered a PARPi rather than chemotherapy; chemotherapy may be offered if a PARPi is not available.

### *Triple-Negative*

In second-line, with or without prior PD-L1 checkpoint inhibitors, clinicians may offer chemotherapy, if sacituzumab govitecan is unavailable.

Patients with triple-negative MBC with germline *BRCA1/2* mutations previously treated with chemotherapy may be offered a PARPi rather than chemotherapy.

## **Third-Line**

### *HER2-Positive*

In the third-line setting, clinicians should offer other HER2-targeted therapy combinations. (For patients with HER2-positive, HR-positive MBC, offer hormonal therapy with or without trastuzumab.)

### *Triple-Negative*

In the third-line setting, triple-negative MBC may be eligible for PARPi (if germline *BRCA1/2* mutation status is known), if not available, then clinicians may offer chemotherapy and/or palliative care.

See [Table 8](#) for other third-line regimens.

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

### ADDITIONAL RESOURCES

More information, including a Data Supplement, slide sets, and clinical tools and resources, is available at [www.asco.org/resource-stratified-guidelines](http://www.asco.org/resource-stratified-guidelines). The Methodology Manual (available at [www.asco.org/guideline-methodology](http://www.asco.org/guideline-methodology)) provides additional information about the methods used to develop this guideline. Patient information is available at [www.cancer.net](http://www.cancer.net).

**ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.**

This guideline is not intended for patients in Maximal settings, as described in [Table 1](#).

In 2020, BC was the most common malignancy worldwide (first most incident in 2020 per Cancer Today—IARC), surpassing lung cancer for the first time in years.<sup>3,4</sup> It was also the fifth most frequent cause of cancer-related mortality and remains the leading cause of cancer mortality among women worldwide.<sup>3,5</sup> Approximately 1.4 million of the 2.26 million new cases of breast cancer (BC)<sup>3</sup> diagnosed in 2020 were made in low- and middle-income countries (LMICs; 62%), increasing the 5-year prevalence to 4.2 million (54%) of the worldwide 7.8 million cases. The proportion of deaths resulting from BC (72%) in LMICs was higher than their share of incidence (62%), indicating a higher case fatality rate ([Tables 2 and 3](#)).<sup>8</sup> These statistics illustrate the importance of focusing on BC control as a major contributor to cancer morbidity and mortality in LMICs. Younger age at presentation is a unique aspect of BC diagnosis in LMICs.<sup>8,9</sup> Two thirds of BC cases in Low- and Middle-Human Development Index (HDI) countries are diagnosed in patients younger than 50 years, as compared with one third of BC cases in High-HDI countries, with a median age at presentation being a decade younger than in High-HDI countries.<sup>5,9</sup> BC in young women has been associated with unique biology, genetics, and inferior outcomes as compared with BC in older women.<sup>10</sup> This unique aspect could partially contribute to the challenge of more advanced presentation as compared with high-income countries.<sup>11</sup> Young age and dense breasts, even in the digital era, remain risk factors for false-negative mammography in patients with symptoms<sup>12</sup>; in addition, advanced stage may be driven by unique biology.<sup>11</sup> Awareness campaigns are important to support early detection, but they can also play an important role in encouraging the population to proceed with diagnosis and treatment. As stated by Al-Sukhun et al in the ASCO Education Book 2022, “most of the time, patients associate expensive medication with dramatic benefit, even if the scientific evidence does not support these expectations. If they cannot afford those expensive medications, they decline treatment or shy away from seeking health care.”<sup>4(p420)</sup> Awareness campaigns must address such expectations and educate patients on the benefit they may

experience from standard surgery, radiation therapy, and affordable medications. Lack of access to high-end technology should not be associated with lack of benefit from treatment of patients with cancer.<sup>8</sup> In resource-constrained settings, efficient allocation of resources mandates prioritization. Many cancer medicines included in the WHO Essential Medicines List (EML) are not available or are expensive in LMICs (see Appendix [Table A4](#)).<sup>13,14</sup> The concept of resource limitations is no longer solely applied to countries defined by income according to the World Bank definition; it is a dynamic concept contingent on the stability of the society or the region of concern and the concept of human development indices.<sup>15-18</sup> The provision of evidence-based and context-appropriate guidance for clinicians has been demonstrated to improve the outcome of patients with BC, supporting a public health approach to best inform clinical decisions in that specific setting.<sup>19</sup>

Anatomic diagnosis is central to the diagnosis and treatment of malignancies at the individual patient level. Histopathologic evaluation assigns subtype and grade and identifies secondary prognostic features and molecular signals that predict prognosis and the choice of therapy for cancer. Pathology and laboratory medicine services face substantial implementation challenges in resource-constrained settings.<sup>20</sup> Those include insufficient human capacity; inadequate infrastructure; inadequate consumables; inadequate education and training; and inadequate quality, standards, and accreditation.<sup>20</sup> Therefore, recommendations on the basis of subtype identification should take into consideration the fact that accurate diagnostics might not be available in Basic settings and should help oncologists treat patients accordingly. The same limitations apply when considering surgical and radiation therapy services. However, there is extreme heterogeneity in access to these services in limited resource settings.<sup>21,22</sup>

Different regions of the world, both among and within countries, have variable access to diagnosis and treatment of BC. In addition, patients' access to medicines may change quickly. Patients with MBC ideally require the care of specialists including medical oncologists who have extensive

**TABLE 1.** Framework of Resource Stratification

Setting	Definition
Basic	Core resources or fundamental services that are absolutely necessary for any public health/primary health care system to function; basic-level services typically are applied in a single clinical interaction. Vaccination is feasible for highest-need populations.
Limited	Second-tier resources or services that are intended to produce major improvements in outcome such as incidence and cost-effectiveness and are attainable with limited financial means and modest infrastructure; limited-level services may involve single or multiple interactions. Universal public health interventions feasible for greater percentage of population than the primary target group.
Enhanced	Third-tier resources or services that are optional but important; enhanced-level resources should produce further improvements in outcome and increase the number and quality of options and individual choice. (Perhaps ability to track patients and links to registries).
Maximal	May use high-resource settings' guidelines High-level/state-of-the-art resources or services that may be used/available in some high-resource countries and/or may be recommended by high-resource setting guidelines that do not adapt to resource constraints but that nonetheless should be considered a lower priority than those resources or services listed in the other categories on the basis of extreme cost and/or impracticality for broad use in a resource-limited environment.

NOTE. Data adapted.<sup>1,2</sup> To be useful, Maximal-level resources typically depend on the existence and functionality of all lower-level resources. Maximal-level recommendations are not included in this guideline.

training. However, outside of specialized centers within High-HDI regions, there is a paucity of specialty training with few clinicians available to skillfully manage these patients. Some of the presumptions inherent in this guideline include that chemotherapy is not available in Basic settings (Table 4). As a result of these disparities, the ASCO Resource-Stratified Guideline Advisory Group chose MBC as a priority topic for guideline development.

ASCO has established a process for the development of resource-stratified guidelines,<sup>23</sup> which includes mixed methods of evidence-based guideline development, adaptation of the clinical practice guidelines of other organizations, and formal expert consensus. This article summarizes the results of that process and presents resource-stratified recommendations (see the Results section).

Although this guideline refers to the sex of people at risk of BC as women, all people with breasts are at risk for BC and the guidelines apply uniformly to all such people. Therefore, despite limited data when it comes to BC in men, the Expert Panel recommends they have access to the same therapeutic options as patients born female as recommended in evidence-based guidelines. In instances in which the guideline draws on data on the basis of gendered research (eg, studies regarding women with BC), the guideline authors describe the characteristics and results of the research as reported.

In developing resource-stratified guidelines, ASCO has adopted its framework from the four-tier resource setting approach (Basic, Limited, Enhanced, Maximal; Table 1) developed by Breast Health Global Initiative and modifications to that framework on the basis of Disease Control Priorities 3.<sup>1,2</sup> The framework emphasizes that variations occur not only between but also within countries with disparities, for example, between rural and urban areas.

\*Full list of recommendations is available in corresponding Tables 5-7.<sup>24</sup>

## GUIDELINE QUESTIONS

This clinical practice guideline addresses the following overarching clinical question: What is the optimal treatment for patients diagnosed with metastatic breast cancer in resource-constrained settings (in three settings: Basic resource settings, Limited resource settings, and Enhanced resource settings)?

## METHODS

### Guideline Development Process

This formal consensus-based guideline product was developed by an international, multidisciplinary Expert Panel, which included two patient representatives and an ASCO guidelines staff member with health research methodology expertise (Appendix Table A1). The Expert Panel met via teleconference and corresponded through e-mail. On the basis of the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. Members of the Expert Panel were responsible for reviewing and approving the penultimate version of the guideline, which was then circulated for external review and submitted to a peer-reviewed journal for editorial review and consideration for publication.

This guideline adaptation was also informed by the ADAPTE methodology and consensus methodology together as an alternative to de novo guideline development for this guideline. Adaptation of guidelines is considered by ASCO in selected circumstances when one or more quality guidelines from other organizations already exist on the same topic. The objective of the ADAPTE process is to take advantage of existing guidelines to enhance efficient production, reduce duplication, and promote the local uptake of quality guideline recommendations.<sup>26</sup>

ASCO's adaptation process begins with a literature search by ASCO guidelines staff to identify candidate guidelines for adaptation. Adapted guideline manuscripts are reviewed and approved by the ASCO Evidence-Based Medicine Committee (EBMC). The review includes content review completed by an Expert Panel (Appendix Table A1). All funding for the administration of the project was

**TABLE 2.** Breast Cancer Incidence and Mortality Categorized by HDI

HDI	Incidence <sup>a</sup>	Age-Standardized Rates <sup>b</sup>	Mortality <sup>c</sup>	Age-Standardized Rates <sup>b</sup>
Low	109,572	36.1	58,586	36.1
Medium	307,658	27.8	147,427	13.6
High	825,438	42.7	247,486	12.1
Very high	1,017,459	75.6	231,093	13.4

NOTE. From 2020 GLOBOCAN IARC.

Abbreviation: HDI, Human Development Index.

<sup>a</sup>Estimated number of new cases, 2020, both sexes.

<sup>b</sup>Age-standardized rates per 100,000 per Cancer Today (IARC, WHO).

<sup>c</sup>Estimated number of deaths, 2020, both sexes.

provided by ASCO. Further details of the methods used for the development of this guideline are reported in the ASCO Guidelines Methodology Manual (available at [www.asco.org/guideline-methodology](http://www.asco.org/guideline-methodology)).

This guideline was partially informed by ASCO’s modified Delphi Formal Expert Consensus methodology, during which the Expert Panel was supplemented by additional experts recruited to rate their agreement with the drafted recommendations. The entire membership of experts is referred to as the Consensus Panel (a list of members is available in Appendix Table A2). In round 1, a total of n = 30 respondents (11 of whom were on the Expert Panel) participated; in round 2, a total of n = 23 respondents (11 of whom were on the Expert Panel) participated. The guideline recommendations were crafted, in part, using the Guidelines

Into Decision Support (GLIDES) methodology.<sup>27</sup> The guideline recommendations were sent for an open comment period of 2 weeks, allowing the public to review and comment on the recommendations after submitting a confidentiality agreement. These comments were taken into consideration while finalizing the guideline. All ASCO guidelines are ultimately reviewed and approved by the Expert Panel and the ASCO EBMC before publication.

**Guideline Disclaimer**

The clinical practice guidelines and other guidance published herein are provided by the ASCO, Inc to assist providers in clinical decision making. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations specify the level of confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should

**TABLE 3.** Breast Cancer Presentation by Stage for Selected Regions

Country/Region	Population	Year	Stage I (%)	Stage II (%)	Stage III (%)	Stage IV (%)	Unstaged/Unknown (%)
South India (Mathew et al) <sup>6</sup>	Kerala (only female) (note: also, association between less education and diagnosis at regional/metastatic stage)	2012-2014	8	38	27	10	17
Estonia (HIC) <sup>7</sup>		2010-2020	29.7	36.6	15.9	8.3	9.5
South Africa (upper MIC) <sup>7</sup>		2010-2020	2.2	8.7	10.8	7.3	71
United States (compared with Estonia and South Africa) (HIC) <sup>7</sup>		2010-2020	39	24	9	4	3
Australia (HIC) <sup>7</sup>		2010-2020	43	34.7	12.1	4.6	5.5
Kazakhstan (upper MIC) <sup>7</sup>		2010-2020	15.7	61.1	17.1	5.7	0.7
Ecuador (upper MIC) <sup>7</sup>		2010-2020	22	40	22	12	0
Belgium (HIC) <sup>7</sup>		2010-2020	45.9	38.4	7.5	8.2	0
Cuba (upper MIC) <sup>7</sup>		2010-2020	27.3	41.6	23.4	5.6	0
Bulgaria (upper MIC) <sup>7</sup>		2010-2020	27.6	45.5	19.5	7.3	0
Brazil (Vianna Cabral; upper MIC)	Belo Horizonte (N = 715)	2010-2013	28	32.4	39.6 (III and IV)		11

NOTE. Primary source: Duggan et al;<sup>7</sup> secondary source: Mathew et al.<sup>6</sup>

Abbreviations: HIC, high-income country; MIC, middle-income country.

**TABLE 4.** Diagnosis, Staging, and Treatment Capacities by Setting

Intervention	Basic	Limited	Enhanced
Imaging	X-ray and US and expertise for interpretation	X-ray/US/CT may be available in some regions CT-/US-guided biopsy available	CT/MRI available
Surgery	General practitioner with basic surgical capacity (can include some ovarian mass diagnostic procedures—not hysterectomy) General surgery facility with minor operating room available with anesthesia	General surgeon, General surgery facility with operating room, Ob/Gyn—by default has some oncology skills	OR, ICU, most major surgeries available, subspecialized oncologists, including surgical oncologists/gyn oncologists
Chemotherapy	Presume not available (for purposes of guidelines) Availability of chemotherapy drugs is unpredictable	Some chemotherapy available (maybe not so specific). Only first-line	More chemotherapy options available, targeted therapy may or may not be available. May be ≥first-line available
Pathology	Sending pathology for review when needed may or may not be available	Pathology services in development H&E usually available; IHC and molecular tests are usually not available	Pathology services usually available, and IHC and molecular tests may be available
Palliative care	Palliative care service is not available. Limited medications for pain may be available	Pain and symptom management available; palliative care service is in development	Palliative care specialty service not always available

Abbreviations: CT, computed tomography; H&E, Hematoxylin and eosin stain; ICU, intensive care unit; IHC, immunohistochemistry; MRI, magnetic resonance imaging; Ob/gyn, obstetrician/gynecologist; OR, operating room; US, ultrasound.

not” indicate that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO does not endorse third party drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions. Any use of a brand or trade name is for identification purposes only. ASCO provides this information on an “as is” basis, and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

### Guideline and Conflicts of Interest

The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at <http://www.asco.org/guideline-methodology>). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker’s bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did

not disclose any relationships constituting a conflict under the Policy.

## RESULTS

### Literature Search

The recommendations were developed through a review of existing Maximal setting ASCO-published guidelines<sup>25,28-33</sup> and clinical experience of the panel of experts. The methods of development of each systematic review-based ASCO guideline are available in each publication. A total of four ASCO guidelines on medical treatment of patients with metastatic breast cancer (MBC) were found. The Expert Panel was aware of three rapid updates published in 2022;<sup>31,32,34</sup> however, since this resource-stratified guideline development started before those publications, the recommendations in this guideline do not necessarily reflect those updates (which are relevant only to Maximal settings).

These ASCO Maximal setting guidelines cover treatment of patients with MBC, both female and male, and with the following subtypes: (1) hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, (2) HER-negative and either endocrine-pretreated or HR-negative (the latter referred to triple-negative in this guideline), and (3) HER2-positive.

The ASCO Expert Panel reviewed these guidelines; Appendix Table A3 lists links to the guidelines. The Expert Panel used these guidelines, literature suggested by the Expert Panel, and clinical experience as guides. The Expert Panel acknowledges the effort put forth by the authors and ASCO to produce evidence-based guidelines informing practitioners and institutions who provide care to patients with MBC.



**TABLE 5. First-Line Systemic Metastatic Breast Cancer Treatment**

Recommendation No.	Population	Basic	Limited	Enhanced
HR-positive, HER2-negative				
1.1.1	HR-positive, HER2-negative Postmenopausal	<i>Tamoxifen</i> , palliative, <sup>a</sup> and best supportive care should be provided Surgery and <i>tamoxifen</i> when patient presents with certain symptoms	Sequential hormone therapy <sup>b</sup> Aromatase inhibitors (AIs) only if ovarian ablation/ovarian suppression (OA/OS) is available <sup>b</sup>	Sequential hormone therapy <sup>b</sup>
1.1.2	HR-positive, HER2-negative with immediately life-threatening disease or in those with rapid visceral recurrence on adjuvant hormone therapy	<i>Tamoxifen</i> Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy Combination regimens may be offered for symptomatic or immediately life-threatening disease	Single-agent chemotherapy Combination regimens may be offered for symptomatic or immediately life-threatening disease
1.1.3	HR-positive, HER2-negative with immediately life-threatening disease w/o prior adjuvant hormone therapy	<i>Tamoxifen</i> Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy Combination regimens may be offered for symptomatic or immediately life-threatening disease	Single-agent chemotherapy Combination regimens may be offered for symptomatic or immediately life-threatening disease for which time may allow only one potential chance for therapy
1.1.4	HR-positive, HER2-negative Postmenopausal w/o prior adjuvant hormone therapy	<i>Tamoxifen</i>	<i>Tamoxifen</i> (nonsteroidal AI if available) Sequential hormone therapy <sup>b</sup>	A nonsteroidal AI <sup>b</sup> and a <b>CDK4/6 inhibitor</b>
1.1.5	HR-positive, HER2-negative Premenopausal	<i>Tamoxifen</i> Bilateral oophorectomy	<i>Tamoxifen</i> or alternate hormone therapy Surgical options, eg, bilateral oophorectomy; other options: OA/OS Sequential hormone therapy if AI <sup>b</sup>	Ovarian suppression or ablation in combination with hormonal therapy (or if without exposure to prior hormone therapy, <i>tamoxifen</i> alone or ovarian suppression alone or ablation alone). Sequential hormone therapy <sup>b</sup>
1.1.6	HR-positive, HER2-negative: postmenopausal Premenopausal with treatment-naïve	<i>Tamoxifen</i>	<i>Tamoxifen</i> or AI <sup>b</sup> Nonsteroidal if available for postmenopausal <i>Tamoxifen</i> with OA/OS if available for premenopausal or AI with OA/OS If male patients, then with a gonadotropin-releasing hormone analog	Nonsteroidal AI <sup>b</sup> and a <b>CDK4/6 inhibitor</b> combined with ovarian function suppression (if male patients, then with a gonadotropin-releasing hormone analog)
1.1.7	HR-positive: recurrence within 1 year of completing adjuvant AI therapy	<i>Tamoxifen</i>	Alternative hormonal treatment ( <i>tamoxifen</i> , SAI, <sup>b</sup> <b>fulvestrant</b> )	<b>Fulvestrant</b> and a <b>CDK4/6 inhibitor</b>
1.1.8	HR-positive: recurrence ≥12 months of completing adjuvant therapy	<i>Tamoxifen</i>	May reuse specific hormone agent	AI <sup>b</sup> + <b>CDK4/6 inhibitor</b> May reuse specific hormone agent
1.1.9	Male breast cancer	<i>Tamoxifen</i>	<i>Tamoxifen</i> or (combined hormone blockage NSAI with LHRH analog)	Hormonal therapy (A nonsteroidal AI and a <b>CDK4/6 inhibitor</b> [with a gonadotropin-releasing hormone analog])
HER2-positive				
1.2.1	HER2-positive (see below for additional options for HR-positive and HER2-positive)	Palliative <sup>a</sup> and best supportive care	Chemotherapy, options include <i>anthracyclines</i> (note: doxorubicin on EML), <i>once weekly paclitaxel</i> , <i>docetaxel</i> , <i>carboplatin</i> <i>Capecitabine</i>	HER2-targeted therapy combined with chemotherapy. Options include <i>trastuzumab</i> , <b>pertuzumab</b> and a taxane If <b>pertuzumab</b> not available, then chemotherapy and <i>trastuzumab</i> If taxane not available, then vinorelbine or platinum
1.2.2	HER2-positive, HR-positive (in special circumstances such as low disease burden, the presence of comorbidities (contradictions to HER2-targeted therapy such as congestive heart failure), and/or the presence of a long disease-free interval)	Single-agent hormone therapy ( <i>tamoxifen</i> ) Hormonal therapy with ovarian ablation	Single-agent chemotherapy with <i>anthracyclines</i> , <i>once weekly paclitaxel</i> , <i>docetaxel</i> , <i>carboplatin</i> , <i>CMF</i> ( <i>cyclophosphamide</i> , <i>methotrexate</i> , <i>fluorouracil</i> ). Hormonal therapy alone (if AI <sup>b</sup> and <i>tamoxifen</i> available)	HER2-targeted therapy ( <i>trastuzumab</i> + <b>pertuzumab</b> ) with chemotherapy or hormonal therapy plus HER2-targeted therapy or hormonal therapy alone (latter in special circumstances) Clinicians should recommend HER2-targeted therapy-based combinations for first-line treatment, except for highly selected patients with ER-positive or PgR-positive and HER2-positive disease for whom clinicians may use endocrine therapy alone In special circumstances, such as low disease burden, the presence of comorbidities (contradictions to HER2-targeted therapy such as congestive heart failure), and/or the presence of a long disease-free interval, clinicians may offer first-line endocrine therapy alone
Triple-negative				
1.3.1	Triple-negative without known PD-L1	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy	Single-agent chemotherapy rather than combination chemotherapy
1.3.2		Palliative <sup>a</sup> and best supportive care		

(continued on following page)

**TABLE 5. First-Line Systemic Metastatic Breast Cancer Treatment (continued)**

Recommendation No.	Population	Basic	Limited	Enhanced
	Triple-negative without known PD-L1 and with symptomatic or immediately life-threatening disease		Single-agent chemotherapy Combination chemotherapy if possible	Single-agent chemotherapy Combination chemotherapy if possible
1.3.3	Triple-negative with known PD-L1 and no contraindications	Palliative <sup>a</sup> and best supportive care (PD-L1 testing not available)	Single-agent chemotherapy	Addition of immune checkpoint inhibitor to chemotherapy ( <b>atezolizumab</b> plus <b>nab-paclitaxel</b> or <b>pembrolizumab</b> plus chemotherapy) as first-line therapy
<i>BRCA</i> mutations (note: the recommendations for patients with HR-positive, HER2-positive, and triple-negative breast cancer are also options for patients when PARPi are not available)				
1.4.1.a	<i>BRCA1/2</i> mutations (HR-positive)	<i>Tamoxifen</i> —If ER-positive, then see ER-positive recommendations and/or HER2-positive, see HER2-positive recommendations Palliative <sup>a</sup> and best supportive care	<i>Tamoxifen</i> with OA AI with OA Single-agent chemotherapy rather than combination chemotherapy	<b>PARPi</b> Single-agent chemotherapy rather than combination chemotherapy
1.4.1.b	<i>BRCA1/2</i> mutations, HR-negative, HER2-negative	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy	<b>PARPi</b> /chemotherapy
1.4.2	HR-positive, HER2-negative, <i>BRCA1/2</i> mutations (no longer benefiting from endocrine therapy)	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease, especially <i>carboplatin</i> as first option	<b>PARPi</b> (in the first- through to third-line setting rather than chemotherapy), if not available, then single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease

NOTE. (1) In Basic settings, the recommendations presume that neither chemotherapy nor targeted therapy or molecular testing are available. Italics = medications on EML (not universally available in low-income and lower-middle-income countries (<50%)). Italics, bold = not on EML. (2) Per the “Palliative Care in the Global Setting: ASCO Resource-Stratified Guideline”<sup>24</sup> recommendations, there should be a coordinated system where the palliative care needs of patients and families are identified and met at all levels, in collaboration with the team providing oncology care. The health care system should have trained personnel who are licensed to prescribe, deliver, and dispense opioids at all levels. Distance communication should be instituted at the national or regional level through oncology centers (or other tertiary care centers) to support those providing oncology care to patients in lower-resource areas. (3) General: palliative care needs should be addressed for all patients with cancer at presentation using appropriate screening, especially when disease-modifying interventions are not available. (4) Patients eligible for PARPi if they previously received chemotherapy for neoadjuvant, adjuvant, or metastatic disease.

Abbreviations: AI, aromatase inhibitor; CMF, cyclophosphamide, methotrexate, fluorouracil; EML, Essential Medicines List; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LHRH, luteinizing hormone–releasing hormone; NSAI, nonsteroidal aromatase inhibitor; OA, ovarian ablation; OS, ovarian suppression; PARPi, poly(ADP-ribose) polymerase inhibitor; PgR, progesterone receptor; SAI, steroidal aromatase inhibitor; w/o, without

<sup>a</sup>Palliative care may or may not include radiation therapy for symptom control.

<sup>b</sup>Patients who are premenopausal: can only receive aromatase inhibitors if accompanied by ovarian ablation or ovarian suppression.

<sup>c</sup>Patients eligible for PARPi they previously received chemotherapy for neoadjuvant, adjuvant, or metastatic disease.

**TABLE 6. Second-Line Systemic Metastatic Breast Cancer Treatment**

Recommendation No.	Population	Basic	Limited	Enhanced
HR-positive, HER2-negative				
2.1.1	HR-positive, HER2-negative, no longer benefiting from endocrine therapy	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease	Single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease
2.1.2	HR-positive, HER2-negative Postmenopausal MBC progressing on prior treatment with nonsteroidal AIs, either before or after treatment with fulvestrant	<i>Tamoxifen</i> if previously not used	<i>Tamoxifen</i> or single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease	<b>Exemestane and everolimus</b>
2.1.3	Postmenopausal women, and male patients, with HR-positive, HER2-negative, <i>PIK3CA</i> mutation, ABC, or MBC following prior endocrine therapy including an AI, with or without a CDK4/6 inhibitor	Palliative <sup>a</sup> and best supportive care	<i>Tamoxifen</i> or single-agent <sup>a</sup> chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease (careful screening for and management of common toxicities are required)	<b>Alpelisib</b> in combination with endocrine therapy in combination with <b>fulvestrant</b> (careful screening for and management of common toxicities are required)
2.1.4	Postmenopausal women, with HR-positive, HER2-negative, without <i>PIK3CA</i> mutation, MBC following prior endocrine therapy including an AI, with or without a CDK4/6 inhibitor	Palliative <sup>a</sup> and best supportive care	<i>Tamoxifen</i> or single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease	Endocrine therapy, AI, or <b>fulvestrant ± everolimus</b>
2.1.5	HR-positive, HER2-negative with recurrence on prior hormone therapy with or without targeted therapy with immediately life-threatening disease or in those with rapid visceral recurrence on adjuvant endocrine therapy	Hormone therapy Palliative <sup>a</sup> care and best supportive care	Single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease	Hormone therapy with or without targeted therapy or single-agent chemotherapy
2.1.6	HR-positive, HER2-negative, with germline <i>BRCA1/2</i> mutation no longer benefiting from hormone therapy	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease especially <i>carboplatin</i> as first option	<b>PARPi</b> Single-agent chemotherapy, combination regimens may be offered for symptomatic or immediately life-threatening disease especially <i>carboplatin</i> as first option
HER2-positive				
2.2.1	HER2-positive	Palliative <sup>a</sup> and best supportive care (HER2 testing likely not available)	Chemotherapy ( <i>anthracyclines</i> , <i>docetaxel</i> , <i>once weekly paclitaxel</i> , <i>carboplatin</i> , <i>CMF</i> ). <i>Capecitabine</i> <b>Capecitabine + lapatinib</b> <i>Trastuzumab</i> with second-line chemotherapy	(1) <b>Trastuzumab deruxtecan</b> If 1 not available, then 2: (2) <b>Trastuzumab emtansine</b> Other options, if 2 not available then 3: (3) <b>Capecitabine + lapatinib</b> If 3 not available then 4: (4) <i>Trastuzumab</i> with second-line chemotherapy
2.2.2	HER2-positive, received HER2-targeted therapy and chemotherapy in first-line	(Total mastectomy for ipsilateral in-breast recurrence if single bone metastasis only). If no medical treatment available, and no pathology, for palliative reasons, including local control, primary surgery in patients who are symptomatic when systemic anti-HER2 therapy is not available	Chemotherapy with <i>anthracyclines</i> , <i>docetaxel</i> <i>once weekly paclitaxel</i> , and <i>carboplatin</i> , <i>CMF</i> <i>Capecitabine</i> Hormonal therapy alone	(1) <b>Trastuzumab deruxtecan</b> If 1 not available, then 2: (2) <b>Trastuzumab emtansine</b> Other options, if 2 not available then 3: (3) <b>Capecitabine + lapatinib</b> If 3 not available then 4: (4) <i>Trastuzumab</i> with second-line chemotherapy

(continued on following page)

**TABLE 6.** Second-Line Systemic Metastatic Breast Cancer Treatment (continued)

Recommendation No.	Population	Basic	Limited	Enhanced
2.2.3	HER2-positive If a patient finished trastuzumab-based adjuvant treatment ≤ 12 months before recurrence	Palliative <sup>a</sup> and best supportive care	Chemotherapy ( <i>anthracyclines, docetaxel, carboplatin, CMF, capecitabine</i> )	(1) <b>Trastuzumab deruxtecan</b> If 1 not available, then 2: (2) <b>Trastuzumab emtansine</b> Other options, if 2 not available then 3: (3) <i>Capecitabine + lapatinib</i> If 3 not available then 4: (4) <i>Trastuzumab</i> with second-line chemotherapy
2.2.4	HER2-positive If a patient finished trastuzumab-based adjuvant treatment >12 months before recurrence	Palliative <sup>a</sup> and best supportive care	Chemotherapy ( <i>anthracyclines, once weekly paclitaxel, docetaxel, carboplatin</i> )	HER2-targeted therapy combined with chemotherapy <i>Trastuzumab, pertuzumab</i> , and a taxane If <b>pertuzumab</b> not available, then chemotherapy and <i>trastuzumab</i> . If taxane not available, then <b>vinorelbine</b> , platinum
Triple-negative				
2.3.1	Triple-negative with known PD-L1 and no contraindications	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy; start with sequencing taxane or platinum; may offer metronomic chemotherapy for disease control	Single-agent chemotherapy rather than combination chemotherapy. Start with sequencing taxane or platinum; may offer metronomic chemotherapy for disease control

NOTE. (1) In Basic settings, the recommendations presume that neither chemotherapy nor targeted therapy or molecular testing are available. Italics = medications on EML (not universally available in low-income and lower-middle-income countries [ $<50\%$ ]). Italics, bold = not on EML. (2) Per the “Palliative Care in the Global Setting: ASCO Resource-Stratified Guideline”<sup>24</sup> recommendations, there should be a coordinated system where the palliative care needs of patients and families are identified and met at all levels, in collaboration with the team providing oncology care. The health care system should have trained personnel who are licensed to prescribe, deliver, and dispense opioids at all levels. Distance communication should be instituted at the national or regional level through oncology centers (or other tertiary care centers) to support those providing oncology care to patients in lower-resource areas. (3) General: palliative care needs should be addressed for all patients with cancer at presentation using appropriate screening, especially when disease-modifying interventions are not available.

Abbreviations: ABC, advanced breast cancer; AI, aromatase inhibitor; CMF, cyclophosphamide, methotrexate, fluorouracil; EML, Essential Medicines List; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast cancer; NA, not available; PARPi, poly(ADP-ribose) polymerase inhibitor.

<sup>a</sup>Palliative care may or may not include radiation therapy for symptom control.

**TABLE 7. Third-Line and Beyond Systemic Metastatic Breast Cancer Treatment**

Recommendation No.	Population	Basic	Limited	Enhanced
Triple-negative				
3.1.1	Triple-negative	Palliative <sup>a</sup> and best supportive care	Palliative <sup>a</sup> and best supportive care	Single-agent chemotherapy rather than combination chemotherapy
3.1.2	Triple-negative with germline <i>BRCA1/2</i> mutations (previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting)	Palliative <sup>a</sup> and best supportive care	<i>PARPi</i> (for those with known mutation status)	<i>PARPi</i> (for those with known mutation status)
HR-positive, <i>BRCA</i> mutation				
3.2.1	HR-positive, germline <i>BRCA1/2</i> mutation	Palliative <sup>a</sup> and best supportive care	<i>PARPi</i> (for those with known mutation status)	<i>PARPi</i> (for those with known mutation status) Single-agent chemotherapy rather than combination chemotherapy
HER2-positive				
3.3.1	HER2-positive	Palliative <sup>a</sup> and best supportive care	Chemotherapy	<i>Trastuzumab emtansine</i>
3.3.2	HER2-positive, HR-positive	Palliative <sup>a</sup> and best supportive care	Hormonal therapy	<i>Trastuzumab</i> + hormonal therapy
3.3.3	Patient is receiving HER2-targeted therapy and chemotherapy combinations (Timing, Duration, Scheduling—ASCO question—what are the optimal timing, dose, schedule, and duration of treatment)	Not relevant	If a patient is receiving HER2-targeted therapy and chemotherapy combinations, the chemotherapy should continue for approximately 4-6 months (or longer) and/or to the time of maximal response, depending on toxicity and in the absence of progression. When chemotherapy is stopped, clinicians should continue the HER2-targeted therapy; no further change in the regimen is needed until the time of progression or unacceptable toxicities	If a patient is receiving HER2-targeted therapy and chemotherapy combinations, the chemotherapy should continue for approximately 4-6 months (or longer) and/or to the time of maximal response, depending on toxicity and in the absence of progression. When chemotherapy is stopped, clinicians should continue the HER2-targeted therapy; no further change in the regimen is needed until the time of progression or unacceptable toxicities

NOTE. (1) In Basic settings, the recommendations presume that neither chemotherapy nor targeted therapy or molecular testing are available. Italics = medications on EML (not universally available in low-income and lower-middle-income countries (<50%)). Italics, Underlined = not on EML. (2) Per the “Palliative Care in the Global Setting: ASCO Resource-Stratified Guideline”<sup>24</sup> recommendations, there should be a coordinated system where the palliative care needs of patients and families are identified and met at all levels, in collaboration with the team providing oncology care. The health care system should have trained personnel who are licensed to prescribe, deliver, and dispense opioids at all levels. Distance communication should be instituted at the national or regional level through oncology centers (or other tertiary care centers) to support those providing oncology care to patients in lower-resource areas. (3) General: palliative care needs should be addressed for all patients with cancer at presentation using appropriate screening, especially when disease-modifying interventions are not available.

Abbreviations: EML, Essential Medicines List; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PARPi, poly(ADP-ribose) polymerase inhibitor.

<sup>a</sup>Palliative care may or may not include radiation therapy for symptom control.

**TABLE 8.** Maximal Setting: Third-Line Options for HER2-Positive Breast Cancer

Recommendation	Strength
If a patient's HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted treatment and the patient has already received <b>pertuzumab</b> and <b>TDxd</b> (if a patient has not received pertuzumab, <b>pertuzumab</b> )	–
If a patient has not received T-DM1 in second-line, <b>T-DM1</b> regimen	Strong
<b>Tucatinib</b> combined with trastuzumab and <b>capecitabine</b>	Strong
<b>Trastuzumab deruxtecan</b>	Strong
<b>Neratinib</b> combined with <b>capecitabine</b>	Weak
<b>Lapatinib</b> and trastuzumab	Weak
<b>Lapatinib</b> and <b>capecitabine</b>	Weak
Other combinations of chemotherapy and trastuzumab	Weak
<b>Margetuximab</b> plus chemotherapy	Weak
If a patient has not received pertuzumab, <b>pertuzumab</b>	Weak
Hormonal therapy (in patients with ER-positive and/or PgR-positive disease)	Weak
<b>Abemaciclib</b> combined with trastuzumab and <b>fulvestrant</b>	Weak

NOTE. Italics, bold = not on EML. Italics = medications on EML (not universally available in low-income and lower-middle-income countries [ $<50\%$ ]). Source: ASCO 2022 guideline.<sup>25</sup>

Abbreviations: EML, Essential Medicines List; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor; TDxd, trastuzumab deruxtecan; T-DM1, trastuzumab emtansine.

In addition, the Panel was surveyed on the availability of ASCO-recommended interventions in their settings. While the sample was small, the results showed that the majority had access to hormonal therapy (including aromatase inhibitors [AIs]) and ovarian suppression or ablation; the following are not available in some settings: nonsteroidal AIs, fulvestrant, CDK4/6 inhibitors, pertuzumab, immunotherapy, poly(ADP-ribose) polymerase inhibitors (PARPis), PIK3CA-targeted therapy, sacituzumab govitecan, everolimus, trastuzumab deruxtecan, and trastuzumab emtansine (T-DM1). In addition, this guideline refers to a publication from Fundytus et al<sup>35</sup> on “Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey;” while this survey was conducted in 2020, it does provide some additional context on clinicians' perceptions of availability.

Furthermore, the Panel sought feedback from international members and their colleagues on the availability of antineoplastic therapy for patients with MBC in resource-constrained settings, LMICs, and low- and middle-income regions during winter 2022–2023. Respondents generally believe that most cytotoxics, hormonal therapies, and earlier anti-HER2 (trastuzumab and occasionally pertuzumab) therapies are available for most individuals through public or private means. Respondents generally believe that eribulin, fulvestrant, nonsteroidal AIs, some

CDK4/6 inhibitors, T-DM1, trastuzumab deruxtecan, tucatinib, alpelisib, sacituzumab govitecan, everolimus, and checkpoint inhibitors are not available for most individuals through public or private means.

## SUMMARY OF ADAPTED GUIDELINES

### Guidelines on Treatment of Patients Diagnosed With MBC

The Expert Panel identified clinical questions and/or categories within the adapted guidelines that would potentially match the ASCO clinical questions for resource-constrained settings. All the guidelines were developed on the basis of patients in Maximal settings, and therefore, the Expert Panel had to review and adapt the recommendations for resource-constrained settings on the basis of experience in resource-constrained settings and then validate the recommendations by formal consensus. The target populations were all in Maximal settings and included patients with MBC.

All the ASCO guidelines this guideline adapted used systematic review-based methods. The key evidence for the guidelines included systematic reviews, randomized clinical trials, clinical experience, and informal consensus. Therefore, many recommendations in this ASCO guideline were informed by this variety of expert-reviewed data and then validated by Formal Consensus.

The outcomes and end points in most studies reviewed by the adapted guidelines included efficacy (including overall survival [OS] and progression-free survival [PFS]), quality of life, and safety or adverse events.

### Results of ASCO Methodological Review

Because this guideline is based on ASCO guidelines, methodological review was not conducted.

## SELECTED RECOMMENDATIONS

The recommendations were developed by a multinational, multidisciplinary group of experts using evidence from the existing guidelines and clinical experience as a guide. The ASCO Expert Panel underscores that health care practitioners who implement the recommendations presented in this guideline should first identify the available resources in their local and referral facilities and endeavor to provide the highest level of care possible with those resources. ASCO Resource-Stratified Guidelines acknowledge that clinicians and medical institutions in resource-constrained settings are striving to provide more effective medications, human and material infrastructure, as well as interact with policymakers. The authors would like to make some general points applying to recommendations throughout this guideline: outcomes should be balanced with quality of life including financial toxicity; recommendations are made

regarding what is feasible in resource-constrained settings in this publication.

Due to the large breadth of recommendations, the Panel elected to discuss selected areas.

### Overarching Clinical Questions on Patients With HR-Positive, HER2-Negative MBC

Recommendations 1.1.1-1.1.9 (first-line), 2.1.1-2.1.6 (second-line), 3.2.1 (patients with HR-positive, *BRCA1/2* mutation-positive MBC included in a separate section).

#### Discussion

The first set of treatment recommendations (Table 5) state that clinicians should recommend treatment with systemic therapy according to pathological and biomarker features when the results of biomarker testing and pathology are available. Basic immunohistochemistry (estrogen receptor [ER], progesterone receptor [PgR], and HER2) is an important step in characterizing the disease and should be sought when possible in every scenario, as this will critically inform treatment decisions.

#### HR-Positive

Using non-steroidal AIs and CDK4/6 inhibitors in the first-line setting is supported by strong evidence, with both PFS and OS benefits as compared with AIs alone according to recent ASCO guidelines. Prior ASCO guidelines also recommended AIs alone, which also provides patient benefit. For patients unable to access CDK4/6 inhibitors, the use of AI alone or tamoxifen is an alternative in Limited resource settings. In clinical presentations with high symptom burden and life-threatening disease (ie, visceral crises), single-agent chemotherapy, if available, and even surgery are acceptable treatment options. For patients who are premenopausal, ovarian suppression or ablation plus hormonal therapy, if available, should be discussed. Surgical ablation or radiotherapy may be recommended whenever feasible as alternatives to medical ovarian suppression.

**Basic resource settings.** Patients should be offered tamoxifen and palliative care according to ASCO Palliative Care Guidelines and, when possible, be referred for treatment in less resource-constrained medical settings. The goal of palliative care is to prevent patient suffering. In patients progressing on tamoxifen, an AI, and later, where systemic chemotherapy is available, single-agent palliative chemotherapy can be offered.

**Limited resource settings.** For patients with HR-positive MBC, offering tamoxifen or an AI (for patients who are postmenopausal) is appropriate even when there is limited access to combination therapy with CDK4/6 inhibitors to avoid interrupted supply. Sequencing AI after disease progression on tamoxifen is also appropriate. Single-agent palliative systemic chemotherapy should be offered when

available in patients whose disease is progressing on endocrine therapy.

**Maximal and Enhanced resource settings.** A combination of endocrine therapy with an AI and a CDK4/6 inhibitor should be the first-line treatment for patients with metastatic HR-positive BC (plus ovarian suppression or ablation for patients who are premenopausal). Further treatment lines should follow standard guidelines exploring hormonal agents while there is evidence of endocrine sensitivity. Once resistance to endocrine alternatives is established, chemotherapies and targeted treatments in selected patients (ie, patients whose cancers are *PI3KCA* or *BRCA1/2* mutated) are indicated.

#### Further Discussion

**Basic resource settings.** Many of the recommendations for patients with HR-positive, HER2-negative MBC emphasize offering tamoxifen in the Basic setting. Since most patients with BC have cancers that are HR-positive,<sup>29</sup> the guideline recommends tamoxifen as a reasonable alternative. While the critical importance of basic immunohistochemistry, the Panel acknowledges that in some Basic settings, HR testing may not be available. As the potential harms of tamoxifen are relatively low, the Panel determined it offering a treatment option for patients in this situation was important. Tamoxifen is the historical mainstay of treatment for patients with HR-positive BC and is a recommended option in ASCO's 2016 guideline and re-affirmed in 2021. However, even tamoxifen may not be available (according to the global survey by Fundytus et al,<sup>35</sup> it was universally available to 36% of oncologists in LMICs, and deemed substantial out-of-pocket expenses by 38% of respondents.) Referring the patients to higher-resource settings, if possible, is recommended.<sup>36</sup>

For patients who are premenopausal, tamoxifen plus ovarian suppression (surgical oophorectomy or radiotherapy ablation, when available) should be recommended rather than medical ovarian suppression strategies. Only surgeons with gynecologic surgical expertise should perform oophorectomies.<sup>37</sup>

**Limited resource settings.** In Limited resource setting recommendations for patients with HR-positive, HER2-negative MBC, sequencing tamoxifen with AIs, and ovarian ablation or suppression in patients who are premenopausal should be discussed. Chemotherapy for patients with resistance to hormonal treatments is appropriate when available. In recommendations 1.1.2, 1.1.3, 2.1.2, and 2.1.5, chemotherapy is an option in the Maximal setting guidelines. In recommendations 2.1.2, 2.1.3, and 2.1.4, the Maximal setting-recommended medical options are not likely available to most patients in the Limited settings, therefore, chemotherapy is an option.

**Enhanced resource settings.** All the recommendations for HR-positive, HER2-negative, *BRCA1/2*-negative, or unknown

correspond to the ASCO Maximal setting recommendations. In situations where patients were previously treated with hormonal adjuvant therapy, it is important to consider the timing of the recurrence or diagnosis of the metastatic disease. Patients with an early recurrence (in the first 2 years of adjuvant hormonal therapy) will likely have endocrine-resistant disease. Patients with a diagnosis of metastatic disease after 12 months of completion of their adjuvant therapy should be noted as more endocrine sensitive and more likely to respond to further hormonal alternatives.

## HER2-Positive

Recommendations 1.2.1-1.2.2, 2.2.1-2.2.4, 3.3.1-3.3.3.

### Discussion

The treatment of patients with MBC is also contingent on the HER2 status of the patient's cancer. It is outside the scope of this resource-stratified guideline to discuss tissue testing. However, quality HER2 testing, such as that recommended by the College of American Pathologists (CAP)-ASCO,<sup>38,39</sup> is unlikely to be available in more resource-constrained settings. In a survey of 191 providers, including 153 from areas termed LMICs in this publication, about 30% of providers could access HER2 testing in private, but not public settings.<sup>40</sup> (While trastuzumab is currently on the EML; is not available in the public systems everywhere [note: according to Fundytus et al,<sup>35</sup> it is only 15% universally available.])

In Basic and Limited resource scenarios, basic targeted anti-HER2 therapies such as trastuzumab are likely not available. In some settings, some of these agents may be available to patients with private health insurance in some resource-constrained regions. In cases where trastuzumab is not available, combination chemotherapy should be discussed. Sequencing single-agent chemotherapies should be the best alternative for patients whose disease is progressing. In Enhanced resource settings, single-agent chemotherapy in combination with available anti-HER2 therapy should be offered.

### HER2-Positive First-Line

Recommendation 1.2.1. The guideline recommends a tiered approach if the ASCO-recommended agents are not available. In Enhanced settings, if pertuzumab isn't available, trastuzumab and chemotherapy or chemotherapy alone are acceptable, as these agents were used historically before the advent of targeted therapy. In addition, navelbine can be used with trastuzumab in the frontline setting if taxanes are not available. The efficacy of navelbine in this setting has been demonstrated in the HERNATA study with similar response rate and OS, but less adverse events.<sup>41</sup> Before this study, vinorelbine plus trastuzumab was presumed to be less effective than docetaxel plus trastuzumab. There was no

difference in efficacy and fewer adverse events in the vinorelbine arm compared to the control arm.

### HER2-Positive Second-Line

Recommendations 2.2.1, 2.2.2, 2.2.3, and 2.2.4. For second-line therapy, especially where the ASCO maximal guideline recommends trastuzumab deruxtecan, a tiered approach is recommended for the Enhanced setting depending on what is available. For example, the most recent HER2-positive guideline (as of this writing) recommended trastuzumab deruxtecan; the previous Maximal setting guideline<sup>42</sup> recommended T-DM1, consequently in Enhanced settings, if trastuzumab deruxtecan is not available, then T-DM1 is recommended, then if T-DM1 is not available, capecitabine and lapatinib are recommended, and if neither are available, then clinicians may offer trastuzumab and chemotherapy. This is the same for recommendation 2.2.2. Recommendation 2.2.4 also provides an additional chemotherapy option in Enhanced settings.

### Surgery of the Primary Tumor

Surgery for a patient's primary tumor is an option recommended for patients with HER2-positive tumors who received HER2-targeted therapy and chemotherapy in the first line. The following section is not based on the ASCO Maximal setting guidelines, but rather literature suggested by the Panel. A separate systematic review was not conducted for this guideline.

The role and potential benefit of removing the primary tumor continue to remain unclear for all patients with advanced-stage BC.<sup>43</sup> Previous studies have provided mixed results about the survival benefit from surgical excision. Prospective trials failed to resolve whether locoregional therapy is<sup>44,45</sup> or is not<sup>46,47</sup> associated with a survival advantage in MBC. Those prospective trials were performed prior to routine assessment of HER2 status. These studies have limitations, including lack of standard randomization by biomarker status, leading to more favorable tumor subtypes in the surgically treated group in the trial demonstrating survival benefit with surgery,<sup>44</sup> while the trial led by Badwe et al<sup>47</sup> did not utilize HER2-targeted therapy in patients with HER2-positive disease. A 2010-2012 retrospective cohort with data from 3,231 women in the National Cancer Database with HER2-positive MBC compared those who did and did not undergo definitive breast surgery showed surgery was associated with a 44% reduction in the risk of death.<sup>48</sup> In addition, a recent systematic review and meta-analysis showed benefit in patients who had limited disease burden, only one metastatic site or bone-only metastasis, or with negative margin at surgery, especially among premenopausal patients.<sup>45,49</sup> Those were consistent with the results reported by Soran et al, where a benefit was also described among patients with ER-positive disease.<sup>44</sup> Therefore, primary tumor surgery in appropriately selected patients with de novo stage IV BC controls locoregional



progression, but discussion continues regarding its impact on OS in patients with oligometastatic or bone-only disease. Until the Expert Panel has further prospective data, especially when medical therapy resources are constrained, surgery of the primary tumor in appropriately selected patients with limited disease burden, bone-only disease, and ER-positive and/or HER2-positive disease, who can attain negative margin on surgery especially those younger than 55 years, is recommended. The Panel acknowledges the controversy surrounding this recommendation, therefore, advise discussion with the patient, emphasizing the palliative benefit and the potentially positive impact considering the data. In addition, the Expert Panel suggests palliative mastectomy for patients with bleeding or progressively ulcerating tumors in spite of available therapy, especially in Basic or Limited settings; whenever radiation therapy is not available.

### Germline (g) BRCA Mutation–Positive (m+)

Recommendations 1.4.1 a, 1.4.1 b, 1.4.2, 2.1.6, 3.2.1.

#### Discussion

For recommendation 1.4.1 a, the ASCO Maximal setting guideline recommends PARPi, which are not recommended in Basic or Limited settings. BRCA testing with or without genetic counseling is likely not available<sup>37</sup> in Basic and Limited resource settings and many patients will remain undiagnosed. PARPi are not offered unless there is a known gBRCA mutation and patients have received chemotherapy in neoadjuvant, adjuvant, or metastatic setting. In addition, treatment with PARPi is most likely not available in these settings. For patients with known gBRCA mutations where PARPi are not available, treatment options for patients with HR-positive disease include hormonal therapy with or without ovarian ablation. For patients with endocrine-refractory disease (single-agent or combination) chemotherapy (recommendations 1.4.2, 2.1.6) is an option.

### Triple–Negative

Recommendation 3.1.2. For patients with triple-negative MBC, that is gBRCA-mutated, who have received prior chemotherapy, third-line and beyond PARPi is recommended in Limited and Enhanced settings as this provides the best chance of increased PFS and response rates as described in the Moy et al guideline.<sup>30</sup>

#### Further Discussion

Radiation and surgical treatment options and government-funded screening programs are dependent on fixed infrastructure and thus face tight resource constraints. Access to medicines, in particular simpler medicines that do not cause cytopenias, may be dependent on an individual's ability to pay and that may change. When it comes to medication prescribing, the resource setting can fluctuate over time,

with geographic and individual circumstances, and the Panel acknowledges this dynamism, as well as clinicians' aspirations to reach best practice. Additional discussion of these issues is available in a companion article.

## SPECIAL COMMENTARY

### Pathology

Pathology is an important part of diagnosing the type of MBC and guiding management of patients with this disease. There are variable availability and financing for pathology services around the world. In some regions, clinicians might even have to make diagnoses without pathology. ASCO Resource–Stratified Guidelines use the capacity framework in [Table 4](#) to guide pathology recommendations. As resource-constrained regions develop pathology services, the Expert Panel offers some suggestions specific to MBC in this Special Commentary section.

The clinical presentation and imaging findings of both benign tumors and other malignancies that can involve the breasts may be similar to or mimic those of MBC. Consequently, a histopathologic diagnosis should be undertaken before definitive treatment. Usually, routine histologic processing of formalin-fixed tissue is sufficient for pathologic diagnosis. Immunohistochemical studies are important in BC diagnosis and do provide additional confirmatory evidence and predictive and prognostic information. In some Limited and Enhanced settings, tissue can be sent to pathology for cell block in major cities. As they become more widely available, recent technological advances such as digital pathology may make pathologic diagnosis available to a larger proportion of patients. However, the Panel recognizes that these technologies are still far from reaching Basic resource settings and most Limited resource scenarios. Pathology laboratories are of variable quality, and investments in pathology have an impact not only in BC diagnosis but also in cancer management and should be seen as a priority in resource allocation and national cancer plans.

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. The expansion of oncology clinical trials in Limited and Enhanced settings is a global oncology priority.

### LIMITATIONS OF THE RESEARCH AND FUTURE DIRECTIONS

There are limitations on the evidence to inform some of the recommendations, because of many recognizable factors, such as prioritization of patient care and limited funding and infrastructure for research in this subject.

When the optimal standard treatments are not available, where there are accessible established regional cancer

**TABLE 9.** Selected Limitations and Future Directions From the Adapted Guidelines

Item	Guideline
"The use of biomarker results to inform the recommendation for use of PARP inhibitors in patients with PALB2 germline mutations and HR-positive, HER2-negative MBC"	Endocrine Treatment and Targeted Therapy for HR+, HER2-Metastatic Breast Cancer (BC)
"PARP inhibitors in patients with germline mutations resulting in defective DNA repair other than <i>BRCA1</i> or <i>BRCA2</i> "	Endocrine Treatment and Targeted Therapy HR+ BC
Future research on "novel endocrine therapies, new targeted agents, and novel combinations"	Endocrine Treatment and Targeted Therapy HR+ BC
"Combinations of CDK4/6 inhibitors and AKT inhibitors"	Endocrine Treatment and Targeted Therapy HR+ BC
"The timing, application, and method (tissue v liquid biopsy) of NGS in HER2-negative, HR-positive, and negative breast tumors remain controversial"	Chemotherapy and Targeted Therapy for Patients With HER2-Metastatic BC That is Either Endocrine-Pre-treated or HR-
"Improved understanding and management of heterogeneity within a metastatic site, between metastatic sites, and over time"	Chemotherapy and Targeted Therapy HER2-, HR- BC
Insufficient information on receiving agents that patients were not previously exposed to if disease relapsed within $\leq 12$ months	Systemic Therapy for Advanced HER2+ BC
Insufficient data to inform the management of patients whose disease relapses or progresses after adjuvant T-DM1	Systemic Therapy for Advanced HER2+ BC
"Route of administration in the metastatic setting"	Systemic Therapy for Advanced HER2+ BC
"Best sequencing of anti-HER2 agents in third-line and beyond"	Systemic Therapy for Advanced HER2+ BC

Abbreviations: CDK, cyclin-dependent kinase; HER2-, human epidermal growth factor receptor 2-negative; HER2+, human epidermal growth factor receptor 2-positive; HR+, hormone receptor-positive; HR-, hormone receptor-negative; MBC, metastatic breast cancer; NGS, next-generation sequencing; PARP, poly(ADP-ribose) polymerase; T-DM1, trastuzumab emtansine.

centers, physicians may refer patients to them, where they might have access. The Expert Panel recognizes that for large parts of the world, there are not established national, let alone regional cancer centers.

Important limitations include insufficient research conducted in resource-constrained settings, lack of conclusive information on primary and preventive screening, and lack of published data on MBC management adapted to resource-constrained settings. Expert recommendations for resource-constrained settings should account for differential access to chemotherapy across Basic and Limited resource settings. A shortage in human resources of trained oncologists has led to task-shifting with variation in skill sets among general practitioners, general surgeons, and oncologists able to manage patients with MBC.

There is a significant need to further MBC research in resource-constrained settings, considering issues of surgery and chemotherapy access, treatment efficacy, and cost-effectiveness. The paucity of cancer research in limited resource settings needs further investigation, which can be achieved through collaborative research. The use of targeted therapy and immunotherapy for patients with MBC is actively under investigation, and further guidelines will include updates. Further limitations are listed in [Table 9](#).

## EXTERNAL REVIEW AND OPEN COMMENT

The draft recommendations were released to the public for open comment from April 12 through April 26, 2023. Response categories of "Agree as written," "Agree with suggested modifications," and "Disagree. See comments" were captured

for every proposed recommendation with 13 written comments received. A total of 81%–100% of the 13 respondents either agreed or agreed with slight modifications to the recommendations, and 0%–19% of the respondents disagreed. Expert Panel members reviewed comments from all sources and determined whether to maintain original draft recommendations, revise with minor language changes, or consider major recommendation revisions. All changes were incorporated before EBMC review and approval.

The draft was submitted to two external reviewers with content expertise; two completed the reviews. It was rated as high quality, and it was agreed that it would be useful in practice. Review comments were reviewed by the Expert Panel and integrated into the final manuscript before approval by the EBMC.

## GUIDELINE IMPLEMENTATION

ASCO guidelines are developed for implementation across health settings. Barriers to implementation include the need to increase awareness of the guideline recommendations among frontline practitioners and patients with MBC and to provide adequate services in the face of limited resources. The guideline Bottom Line Box was designed to facilitate implementation of recommendations. This guideline will be distributed widely, including through many forms of ASCO communications and the ASCO website.

## ADDITIONAL RESOURCES

Additional information including a Data Supplement, evidence tables, and clinical tools and resources can be found

at [www.asco.org/resource-stratified-guidelines](http://www.asco.org/resource-stratified-guidelines). Patient information is available there and at [www.cancer.net](http://www.cancer.net).

## GENDER-INCLUSIVE LANGUAGE

ASCO is committed to promoting the health and well-being of individuals regardless of sexual orientation or gender identity.<sup>50</sup> Transgender and nonbinary people, in particular, may face multiple barriers to oncology care including stigmatization, invisibility, and exclusiveness. One way that exclusiveness or lack of accessibility may be communicated is through gendered language that makes presumptive links between sex and anatomy.<sup>51-54</sup> With the acknowledgment that ASCO guidelines may affect the language used in clinical and research settings, ASCO is committed to creating gender-inclusive guidelines. For this reason, guideline authors use gender-inclusive language whenever possible throughout the guidelines. In instances in which the guideline draws upon data on the basis of gendered research (eg, studies regarding women with BC), the guideline authors describe the characteristics and results of the research as reported.

## AFFILIATIONS

- <sup>1</sup>Al Hyatt Oncology Practice, Amman, Jordan  
<sup>2</sup>American Society of Clinical Oncology, Alexandria, VA  
<sup>3</sup>Oncoclinicas Group, Porto Alegre, Brazil  
<sup>4</sup>Institutul Oncologic Prof Dr Ion Chiricuta, Cluj-Napoca, Romania  
<sup>5</sup>Departamento de Hemato-Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico  
<sup>6</sup>University of Texas MD Anderson Cancer Center, Houston, TX  
<sup>7</sup>Gurugram, India  
<sup>8</sup>Virginia Oncology Associates, Norfolk, VA  
<sup>9</sup>Institute Nac de Enfermedades Neoplas, Surquillo, Peru  
<sup>10</sup>CHU Treichville, Abidjan, Cote d'Ivoire  
<sup>11</sup>Alexandria Comprehensive Cancer Center, Alexandria, Egypt  
<sup>12</sup>Kilele Health Association, Nairobi, Kenya  
<sup>13</sup>Flinders Medical Centre, Bedford Park, Australia  
<sup>14</sup>Massachusetts General Hospital, Boston, MA  
<sup>15</sup>Uganda Women's Cancer Support Organisation, Kampala, Uganda  
<sup>16</sup>Instituto Alexander Fleming, Buenos Aires, Argentina  
<sup>17</sup>University of California San Francisco, San Francisco, CA  
<sup>18</sup>American University of Beirut, Beirut, Lebanon

## CORRESPONDING AUTHOR

American Society of Clinical Oncology, 2318 Mill Rd, Ste 800, Alexandria, VA 22314; e-mail: [guidelines@asco.org](mailto:guidelines@asco.org).

## EDITOR'S NOTE

This ASCO Guideline provides recommendations, with comprehensive review and analyses of the relevant literature for each recommendation. Additional information, including a supplement with additional evidence tables, slide sets, clinical tools and resources, and links to patient information at [www.cancer.net](http://www.cancer.net), is available at [www.asco.org/resource-stratified-guidelines](http://www.asco.org/resource-stratified-guidelines).

## RELATED ASCO GUIDELINES

### Resource-Stratified Guidelines

- Palliative Care in the Global Setting<sup>24</sup> (<http://ascopubs.org/doi/10.1200/JGO.18.00026>)

### Non-Resource-Stratified Guidelines

- Integration of Palliative Care into Standard Oncology Practice<sup>55</sup> (<http://ascopubs.org/doi/10.1200/JCO.2016.70.1474>)
- ASCO Breast Cancer Guidelines ([www.asco.org/breast-cancer-guidelines](http://www.asco.org/breast-cancer-guidelines))
- Patient-Clinician Communication<sup>56</sup> (<http://ascopubs.org/doi/10.1200/JCO.2017.75.2311>)

## EQUAL CONTRIBUTION

S.A.S. and B.K.A. were coauthors.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Sana Al Sukhun, Sarah Temin, Nicoleta Zenovia Antone, Nagi S. El Saghir, Banu K. Arun  
**Administrative support:** Sana Al Sukhun, Sarah Temin, Banu K. Arun  
**Collection and assembly of data:** All authors  
**Data analysis and interpretation:** All authors  
**Manuscript writing:** All authors  
**Final approval of manuscript:** All authors  
**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted.

I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/go/authors/author-center](http://ascopubs.org/go/authors/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://www.openpayments.gov)).

### Carlos H. Barrios

**Stock and Other Ownership Interests:** MedSIR, Tummi

**Honoraria:** Novartis, Roche/Genentech, Pfizer, Sanofi, Eisai, MSD, Lilly, Bayer, AstraZeneca, Zodiac Pharma, Adium Pharma, Daiichi Sankyo/AstraZeneca

**Consulting or Advisory Role:** Roche/Genentech, Novartis, Pfizer, AstraZeneca, Libbs, MSD Oncology, United Medical, Lilly

**Research Funding:** Pfizer (Inst), Novartis (Inst), Amgen (Inst), AstraZeneca (Inst), Roche/Genentech (Inst), Lilly (Inst), Sanofi (Inst), Merrimack (Inst), Merck (Inst), Astellas Pharma (Inst), Biomarin (Inst), Bristol Myers Squibb

(Inst), Daiichi Sankyo (Inst), Exelixis (Inst), Janssen (Inst), INC Research (Inst), Covance (Inst), Celgene (Inst), Gilead Sciences (Inst), Bayer (Inst), Nektar (Inst), Exelixis (Inst), Regeneron (Inst), Aveo (Inst), Servier (Inst), OBI Pharma (Inst), Novocure (Inst), Takeda (Inst), TRIO US (Inst), PharmaMar (Inst), PPD Global (Inst), Syneos Health (Inst), LabCorp (Inst), ICON Clinical Research (Inst), IQvia (Inst), Parexel (Inst), Parexel (Inst), Nuvisan (Inst), PSI (Inst), Worldwide Clinical Trials (Inst)

**Travel, Accommodations, Expenses:** Roche/Genentech, Novartis, Pfizer, BMS Brazil, AstraZeneca, MSD Oncology, Lilly

**Yanin Chavarri Guerra**

**Speakers' Bureau:** InVita

**Research Funding:** Roche

**Travel, Accommodations, Expenses:** Roche, Novartis

**Mariana Chavez-MacGregor**

**Employment:** MD Anderson Physician's Network

**Consulting or Advisory Role:** Exact Sciences, AstraZeneca/Daiichi Sankyo, Pfizer, Abbott Laboratories, Exact Sciences, Pfizer, Lilly, AstraZeneca/Daiichi Sankyo, Exact Sciences, Roche/Genentech, Adium Pharma, Merck

**Research Funding:** Novartis (Inst), Genentech/Roche (Inst), Pfizer (Inst), Lilly

**Expert Testimony:** Lilly

**Travel, Accommodations, Expenses:** AstraZeneca, Exact Sciences, Zodiac Pharma

**Uncompensated Relationships:** Legacy Healthcare Services, The Hope Foundation

**Michael A. Danso**

**Honoraria:** Amgen

**Consulting or Advisory Role:** Novartis, Pfizer, Immunomedics, Seagen

**Henry Leonidas Gomez**

**Consulting or Advisory Role:** AstraZeneca

**Speakers' Bureau:** Roche, AstraZeneca, Bristol Myers Squibb

**Research Funding:** MSD Oncology

**N'Da Marcelin Homian**

**Travel, Accommodations, Expenses:** Roche

**Benda Kithaka**

**Employment:** Laboratory & Allied (Lab & Allied) Limited

**Travel, Accommodations, Expenses:** Merck Serono, Qiagen, Roche  
**Other Relationship:** Abbott Diagnostics (Inst)

**Bogda Koczwara**

**Employment:** Australian Radiology Clinics

**Beverly Moy**

**Consulting or Advisory Role:** HRA Pharma

**Fernando Enrique Petracci**

**Honoraria:** Pfizer, Roche, Novartis

**Consulting or Advisory Role:** Pint Pharma

**Expert Testimony:** Novartis, Novartis

**Hope S. Rugo**

**Consulting or Advisory Role:** Napo Pharmaceuticals, Puma Biotechnology, Mylan, Eisai, Daiichi Sankyo

**Research Funding:** OBI Pharma (Inst), Pfizer (Inst), Novartis (Inst), Lilly (Inst), Merck (Inst), Daiichi Sankyo (Inst), Sermonix Pharmaceuticals (Inst), AstraZeneca (Inst), Gilead Sciences (Inst), Astellas Pharma (Inst), Pionyr (Inst), Taiho Oncology (Inst), Veru (Inst), GlaxoSmithKline (Inst), Hoffmann-La Roche AG/Genentech, Inc (Inst)

**Travel, Accommodations, Expenses:** Merck, AstraZeneca, Gilead Sciences

**Open Payments Link:** <https://openpaymentsdata.cms.gov/>

**Nagi S. El Saghir**

**Honoraria:** Roche, Novartis, Pfizer, MSD Oncology, Lilly, Pierre Fabre

**Banu K. Arun**

**Research Funding:** AstraZeneca (Inst)

No other potential conflicts of interest were reported.

## ACKNOWLEDGMENT

The Expert Panel would like to thank external reviewers: Dr Fatima Cardoso, Dr Zeba Aziz, and EBMC reviewers: Dr Dorothy Lombe, Dr Michael Mullane, and the EBMC for their thoughtful reviews and insightful comments on this guideline adaptation. The Expert Panel also thanks the Consensus Panel Members for their review of the guideline recommendations.

## REFERENCES

- Anderson BO, Shyyan R, Eniu A, et al: Breast cancer in limited-resource countries: An overview of the Breast Health Global Initiative 2005 guidelines. *Breast J* 12:S3-S15, 2006 (suppl 1)
- Horton S, Gauvreau CL: Cancer in low- and middle-income countries: An economic overview, in Gelband H, Jha P, Sankaranarayanan R, et al (eds): *Cancer: Disease Control Priorities, Volume 3* (ed 3). Washington, DC, International Bank for Reconstruction and Development/World Bank, 2015
- Sung H, Ferlay J, Siegel RL, et al: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71:209-249, 2021
- Ferlay J, Colombet M, Soerjomataram I, et al: Cancer statistics for the year 2020: An overview. *Int J Cancer* 149:778-789, 2021
- International Agency for Research on Cancer: *Cancer Today*, 2020. <https://gco.iarc.fr/today>
- Mathew A, George PS, Ramadas K, et al: Sociodemographic factors and stage of cancer at diagnosis: A population-based study in south India. *JCO Glob Oncol* 10.1200/JGO.18.00160
- Duggan C, Trapani D, Ilbawi AM, et al: National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: A population-based analysis. *Lancet Oncol* 22:1632-1642, 2021
- Al-Sukhun S, Tbaishat F, Hammad N: Breast cancer priorities in limited-resource environments: The price-efficacy dilemma in cancer care. *Am Soc Clin Oncol Educ Book* 42:1-7, 2022
- Heer E, Harper A, Escandor N, et al: Global burden and trends in premenopausal and postmenopausal breast cancer: A population-based study. *Lancet Glob Health* 8:e1027-e1037, 2020
- Johnson RH, Anders CK, Litton JK, et al: Breast cancer in adolescents and young adults. *Pediatr Blood Cancer* 65:e27397, 2018
- Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med* 367:1998-2005, 2012
- Häberle L, Fasching PA, Brehm B, et al: Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. *Int J Cancer* 139:1967-1974, 2016
- Ruff P, Al-Sukhun S, Blanchard C, et al: Access to cancer therapeutics in low- and middle-income countries. *Am Soc Clin Oncol Educ Book* 35:58-65, 2016
- Cortes J, Perez-García JM, Llombart-Cussac A, et al: Enhancing global access to cancer medicines. *CA Cancer J Clin* 70:105-124, 2020
- The Lancet Oncology: Conflict in Ukraine and its impact on cancer care. *Lancet Oncol* 23:439, 2022
- Spiegel P, Khalifa A, Mateen FJ: Cancer in refugees in Jordan and Syria between 2009 and 2012: Challenges and the way forward in humanitarian emergencies. *Lancet Oncol* 15:e290-e297, 2014
- Wiese D, Stroup AM, Crosbie A, et al: The impact of neighborhood economic and racial inequalities on the spatial variation of breast cancer survival in New Jersey. *Cancer Epidemiol Biomarkers Prev* 28:1958-1967, 2019
- United Nations Development Programme: *Human Development Index*, 2023. <https://hdr.undp.org/data-center/human-development-index#/indicies/HDI>
- Hunter N, Dempsey N, Tbaishat F, et al: Resource-stratified guideline-based cancer care should be a priority: Historical context and examples of success. *Am Soc Clin Oncol Educ Book* 40:1-10, 2020
- Wilson ML, Fleming KA, Kuti MA, et al: Access to pathology and laboratory medicine services: A crucial gap. *Lancet* 391:1927-1938, 2018
- Al-Sukhun S, de Lima Lopes G Jr, Gospodarowicz M, et al: Global health initiatives of the international oncology community. *Am Soc Clin Oncol Educ Book* 37:395-402, 2017
- Chornokur G, Amankwah EK, Schildkraut JM, et al: Global ovarian cancer health disparities. *Gynecol Oncol* 129:258-264, 2013
- Al-Sukhun S, Temin S, Chavez-MacGregor M, et al: ASCO resource-stratified guidelines: Methods and opportunities. *JCO Glob Oncol* 10.1200/JGO.18.00113
- Osman H, Shrestha S, Temin S, et al: Palliative care in the global setting: ASCO resource-stratified practice guideline. *JCO Glob Oncol* 10.1200/JGO.18.0002
- Giordano SH, Franzoi MAB, Temin S, et al: Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. *J Clin Oncol* 40:2612-2635, 2022

26. The ADAPTE Collaboration: The ADAPTE Process: Resource Toolkit for Guideline Adaptation. Version 2.0, 2009. <https://g-i-n.net/wp-content/uploads/2021/05/ADAPTE-Resource-toolkit-V2.1-March-2010-updated-disclaimer.pdf>
27. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. *J Am Med Inform Assoc* 19:94-101, 2012
28. Burstein HJ, Somerfield MR, Barton DL, et al: Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. *J Clin Oncol* 39:3959-3977, 2021
29. Rugo HS, Rumble RB, Macrae E, et al: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. *J Clin Oncol* 34:3069-3103, 2016
30. Moy B, Rumble RB, Come SE, et al: Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. *J Clin Oncol* 39:3938-3958, 2021
31. Moy B, Rumble RB, Carey LA, et al: Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation update. *J Clin Oncol* 40:3088-3090, 2022
32. Moy B, Rumble RB, Carey LA, et al: Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update. *J Clin Oncol* 41:1318-1320, 2023
33. Hassett MJ, Somerfield MR, Baker ER, et al: Management of male breast cancer: ASCO guideline. *J Clin Oncol* 38:1849-1863, 2020
34. Wolff AC, DeMichele A, Somerfield MR, et al: Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. *J Clin Oncol* 41:3423-3425, 2023
35. Fundytus A, Sengar M, Lombe D, et al: Access to cancer medicines deemed essential by oncologists in 82 countries: An international, cross-sectional survey. *Lancet Oncol* 22:1367-1377, 2021
36. Anderson BO, Cazap E, El Saghir NS, et al: Optimisation of breast cancer management in low-resource and middle-resource countries: Executive summary of the breast health global initiative consensus, 2010. *Lancet Oncol* 12:387-398, 2011
37. Vanderpuye VD, Clemenceau JRV, Temin S, et al: Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline. *JCO Glob Oncol* 10.1200/GO.21.00085
38. Wolff AC, Hammond MEH, Allison KH, et al: Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med* 142:1364-1382, 2018
39. Wolff AC, Somerfield MR, Dowsett M, et al: Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. *J Clin Oncol* 41:3867-3872, 2023
40. Trapani D, Lengyel CG, Habeeb BS, et al: The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. *J Cancer Policy* 28:100285, 2021
41. Andersson M, Lidbrink E, Bjerre K, et al: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. *J Clin Oncol* 29:264-271, 2011
42. Giordano SH, Temin S, Kirshner JJ, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 32:2078-2099, 2014
43. Tosello G, Torloni MR, Mota BS, et al: Breast surgery for metastatic breast cancer. *Cochrane Database Syst Rev* 3:CD011276, 2018
44. Soran A, Ozmen V, Ozbas S, et al: Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. *Ann Surg Oncol* 25:3141-3149, 2018
45. Soran A: Are we close to the end of the primary tumor resection discussion for de novo stage IV BC? *Eur J Surg Oncol* 45:81-82, 2019
46. Khan SA, Zhao F, Goldstein LJ, et al: Early local therapy for the primary site in de novo stage IV breast cancer: Results of a randomized clinical trial (EA2108). *J Clin Oncol* 40:978-987, 2022
47. Badwe R, Gupta S, Nair N, et al: Survival of patients with metastatic breast cancer with or without locoregional therapy—Authors' reply. *Lancet Oncol* 16:e587-e588, 2015
48. Mudgway R, Chavez de Paz Villanueva C, Lin AC, et al: The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy. *Ann Surg Oncol* 27:2711-2720, 2020
49. Xiao W, Zou Y, Zheng S, et al: Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis. *Eur J Surg Oncol* 44:1504-1512, 2018
50. Griggs J, Maingi S, Blinder V, et al: American Society of Clinical Oncology position statement: Strategies for reducing cancer health disparities among sexual and gender minority populations. *J Clin Oncol* 35:2203-2208, 2017
51. Alpert AB, Manzano C, Ruddick R: Degendering Oncologic Care and Other Recommendations to Eliminate Barriers to Care for Transgender People with Cancer. ASCO Daily News, 2021. <https://dailynews.ascopubs.org/doi/10.1200/ADN.21.200433/full/>
52. Alpert AB, Gampa V, Lytle MC, et al: I'm not putting on that floral gown: Enforcement and resistance of gender expectations for transgender people with cancer. *Patient Educ Couns* 104:2552-2558, 2021
53. Understanding Transgender People: The Basics. National Center for Transgender Equality. <https://transequality.org/issues/resources/understanding-transgender-people-the-basics>, 2022
54. UCSF Gender Affirming Health Program DoFaCM, University of California San Francisco: UCSF Gender Affirming Health Program, Department of Family and Community Medicine, University of California San Francisco: Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, in Deutsch MB (ed): (ed 2), 2016. [transcare.ucsf.edu/guidelines](https://transcare.ucsf.edu/guidelines)
55. Ferrell BR, Temel JS, Temin S, et al: Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 35:96-112, 2017
56. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 35:3618-3632, 2017
57. WHO: WHO Electronic Essential Medicines List (eEML). World Health Organization, 2022. <https://list.essentialmeds.org/>

## APPENDIX

TABLE A1. Treatment of Metastatic Breast Cancer: ASCO Resource–Stratified Guideline Expert Panel Membership

Name	Affiliation or Institution	Role or Area of Expertise
Sana Al Sukhun, MD, MSc, FASCO	Al Hyatt Oncology Practice, Amman, Jordan	Medical Oncology/Hematology
Banu K. Arun, MD	University of Texas MD Anderson Cancer Center, Houston, TX	Medical Oncology
Nicoleta Zenovia Antone, MD	Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania	Medical Oncology
Carlos H. Barrios, MD	Oncoclinicas Group, Porto Alegre, Brazil	Medical Oncology
Yanin Chavarri Guerra, MD, MSc	Departamento de Hemato-Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico	Medical Oncology
Mariana Chavez Mac Gregor, MD, MSc, FASCO	University of Texas MD Anderson Cancer Center, Houston, TX	Medical Oncology
Rakesh Chopra, MD	Self-Employed, Gurugram, India	Medical Oncology/Hematology
Michael A. Danso, MD, FASCO	Virginia Oncology Associates, Norfolk, VA	Medical Oncology
Henry Leonidas Gomez, MD, PhD	Institute Nac de Enfermedades Neoplas, Surquillo, Peru	Medical Oncology
N'Da Marcelin Homian, MD	CHU Treichville, Abidjan, Cote d'Ivoire	Medical Oncology
Alaa Kandil, MD	Alexandria Comprehensive Cancer Center, Alexandria, Egypt	Medical Oncology
Benda Kithaka	Kilele Health Association, Nairobi, Kenya	Patient Representative
Bogda Koczwara, MD	Flinders Medical Centre, Bedford Park, Australia	Medical Oncology
Beverly Moy, MD, FASCO, MPH	Massachusetts General Hospital, Boston, MA	Medical Oncology
Gertrude Nakigudde	Uganda Women's Cancer Support Organisation, Kampala, Uganda	Patient Representative
Fernando Enrique Petracci, MD	Instituto Alexander Fleming, Buenos Aires, Argentina	Medical Oncology
Hope S. Rugo, MD, FASCO	University of California San Francisco, San Francisco, CA	Medical Oncology/Hematology
Nagi S. El Saghir, MD, FASCO	American University of Beirut, Beirut, Lebanon	Medical Oncology
Sarah Temin, MSPH	American Society of Clinical Oncology, Alexandria, VA	ASCO Practice Guidelines Staff (Health Research Methods)

**TABLE A2. Systemic Treatment of Metastatic Breast Cancer: ASCO Resource–Stratified Guideline Consensus Panel Membership**

Name	Affiliation
Amada Andersen	Jefa de Hospital Día–Instituto Nacional del Cáncer, Capiatá, Paraguay
Paula Cabrera-Galeana	Instituto Nacional de Cancerología Mexico, Mexico City, Mexico
Priscilla Baetiong Caguioa, MD	Santo Tomas University Hospital, Manilla, The Philippines
Fatima Cardoso, MD	Champalimaud Cancer Center, Lisbon, Portugal
Aumilto Augusto da Silva Jr.	Hospital Santa Catarina Oncologia, São Paulo, Brazil
Thitiya Sirisinha Dejthevaporn	Faculty of Medicine, Ramathibodi Hospital, Dept of Medicine, Bangkok, Thailand
Kelechi Ngozi Eguzo, MD, MPH	University of Saskatchewan, Regina, Saskatchewan, Canada
Maria Alice B Franzoi, MD	Gustave Roussy Cancer Center, Villejuif Cedex, France
Debora De Melo Gagliato, MD	Hospital Beneficencia Portuguesa de São Paulo, São Paulo, Brazil
Marwan Ghosn, MD, MHA	Faculty of Medicine-Saint Joseph University, Beirut, Lebanon
Sharon H. Giordano, MD, MPH, FASCO	University of Texas MD Anderson Cancer Center, Houston, TX
Bahadir M Gulluoglu, MD, FACS	Marmara University School of Medicine, Çamçeşme, Turkey
Muhammad Abbas Khokhar, MD, FCPS, MBBS	King Edward Medical University, Lahore, Pakistan
Jorge Henrique Santos Leal, MD, MSc	CLION–Grupo CAM, Salvador, Brazil
Precious Takondwa Makondi, PhD, MBBS	Kamuzu Central Hospital–National Cancer Center, Lilongwe, Malawi
William Armando Mantilla, MD, MSc	Fundación CTIC, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogotá, Colombia
Joel Moreno, MD	Instituto Oncologico Nacional, Panamá, Panamá
Alex Mutombo Baleka, MD, PhD	Kinshasa University Hospital, Kinshasa, Democratic Republic of Congo
Sami Saleem Omar	Rizgary Teaching Hospital, Erbil, Iraq
Ravi Sekhar Patnaik, MD, DM, MBBS	The Brunei Cancer Centre, Sengkurong, Brunei
Keechilat Pavithran, MD, DM, FCRP	Amrita Institute of Medical Sciences and Research Center, Ernakulam, India
Mario Perez, MD	Hospital Oncologia del CMN Siglo XXI del IMSS, Mexico City, Mexico
Tiara Bunga Mayang Permata, MD, PhD	Faculty of Medicine Universitas Indonesia–Dr. Cipto Mangunkusumo National General Hospital, Jakarta Pusat, Indonesia
Narmin Mazahir Talibova, MD, MSc	Comprehensive Cancer Center Ulm, Baku, Azerbaijan
Gerardo Antonio Umanzor Fúnez, MD	Liga Contra El Cáncer, San Pedro Sula, Honduras
Mauro Zukin, MD	Oncologia D' Or, Rio de Janeiro, Brazil

**NOTE.** Disclosures of potential conflicts of interest provided by the Consensus Panel Members are available in the guideline Data Supplement.

**TABLE A3. Adapted Guidelines and Links**

Citation	Title	URL
Burstein et al <sup>28</sup>	Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update	<a href="https://ascopubs.org/doi/10.1200/JCO.21.01392">https://ascopubs.org/doi/10.1200/JCO.21.01392</a>
Rugo et al <sup>29</sup>	Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: ASCO Guideline	<a href="https://ascopubs.org/doi/10.1200/JCO.2016.67.1487">https://ascopubs.org/doi/10.1200/JCO.2016.67.1487</a>
Moy et al <sup>30</sup>	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update	<a href="https://ascopubs.org/doi/10.1200/JCO.21.01374">https://ascopubs.org/doi/10.1200/JCO.21.01374</a>
Moy et al <sup>31</sup>	Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update	<a href="https://ascopubs.org/doi/10.1200/JCO.22.01533">https://ascopubs.org/doi/10.1200/JCO.22.01533</a>
Moy et al <sup>32</sup>	Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update	<a href="https://ascopubs.org/doi/10.1200/JCO.22.02807">https://ascopubs.org/doi/10.1200/JCO.22.02807</a>
Giordano et al <sup>25</sup>	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update	<a href="https://ascopubs.org/doi/10.1200/JCO.22.00519">https://ascopubs.org/doi/10.1200/JCO.22.00519</a>
Hassett et al <sup>33</sup>	Management of Male Breast Cancer: ASCO Guideline	<a href="https://ascopubs.org/doi/10.1200/JCO.19.03120">https://ascopubs.org/doi/10.1200/JCO.19.03120</a>

**TABLE A4. WHO Model List of Essential Medicines for Metastatic Breast Cancer**

EML <sup>57</sup>
Anastrozole
Carboplatin
Cyclophosphamide
Docetaxel
Doxorubicin
Fluorouracil (5-fluorouracil)
Goserelin
Leuprorelin
Methotrexate
Paclitaxel
Tamoxifen
Triptorelin

NOTE. This is an adaptation of an original work by WHO. Views and opinions expressed in the adaptation are the sole responsibility of the author or authors of the adaptation and are not endorsed by WHO. Any mediation relating to disputes arising under the license shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.